Provided by Tiger Trade Technology Pte. Ltd.

ZAI LAB

14.050
+0.5404.00%
Volume:5.08M
Turnover:70.40M
Market Cap:15.85B
PE:-11.20
High:14.080
Open:13.500
Low:13.350
Close:13.510
52wk High:35.500
52wk Low:12.310
Shares:1.13B
HK Float Shares:1.13B
Volume Ratio:1.47
T/O Rate:0.45%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.255
ROE:-22.56%
ROA:-12.16%
PB:2.83
PE(LYR):-11.20
PS:4.40

Loading ...

Zai Lab Says Bemarituzumab Study Stopped for Inadequate Efficacy

MT Newswires Live
·
Nov 05, 2025

BRIEF-Zai Lab Updates On Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study

Reuters
·
Nov 05, 2025

Zai Lab (09688) Provides Update on Amgen's Bemarituzumab Phase 1b/3 FORTITUDE-102 Clinical Trial

Stock News
·
Nov 05, 2025

Zai Lab Reports Amgen Halts Phase 1b/3 FORTITUDE-102 Trial for Bemarituzumab in Gastric Cancer

Reuters
·
Nov 05, 2025

Zai Lab Ltd - Update on Amgen's Bemarituzumab Phase 1B/3 Fortitude-102 Study

THOMSON REUTERS
·
Nov 05, 2025

Zai Lab CFO Yajing Chen Reports Disposal of Common Shares

Reuters
·
Nov 05, 2025

Zai Lab Ltd expected to post a loss of 4 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

JPMorgan Increases Stake in Zai Lab (09688) by Approximately 611,105 Shares at HK$20.56 per Share

Stock News
·
Oct 31, 2025

HK Movers|Biotech Shares Soar. 3SBIO up 11%; RemeGen up 8%; SKB BIO up 7%; Junshi Bio up 5%; Hengrui Pharma and Innocare up 4%.

Tiger Newspress
·
Oct 31, 2025

UBS Initiates “Buy” Rating on Zai Lab (09688) with Clear Catalysts Ahead but Undervalued

Stock News
·
Oct 27, 2025

Zai Lab Unveils Promising Phase 1 Data for DLL3 ADC; Launches Global Phase 3 Trial

Reuters
·
Oct 24, 2025

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (Formerly Zl-1310), Demonstrating Potential as a First-in-Class/Best-in-Class Dll3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study

THOMSON REUTERS
·
Oct 24, 2025

Zai Lab Ltd: First-Line Sclc & Neuroendocrine Carcinoma Programs Advancing Toward Registrational Phase in 2026

THOMSON REUTERS
·
Oct 24, 2025

Zai Lab Ltd - Global Phase 3 Trial Initiated for Second-Line Sclc

THOMSON REUTERS
·
Oct 24, 2025

Zai Lab Launches Global Phase 3 Trial of DLL3-Targeted ADC for Small Cell Lung Cancer

Reuters
·
Oct 24, 2025

Zai Lab Limited (Stock Code: 9688) Announces Audit Committee Action and Q3 2025 Results Release Schedule

Bulletin Express
·
Oct 23, 2025

Zai Lab Limited Announces Updated Nominating and Corporate Governance Committee Charter

Bulletin Express
·
Oct 23, 2025

Stock Track | Zai Lab Plummets 5.23% Following RMB300 Million Loan Guarantee Agreement

Stock Track
·
Oct 17, 2025

Stock Track | Zai Lab Plummets 5.23% Following Announcement of RMB300 Million Guarantee Contract

Stock Track
·
Oct 17, 2025

Zai Lab Secures 300 Million Yuan Credit Line

MT Newswires Live
·
Oct 17, 2025